Oral Wegovy Pill vs Injectable: Which Is Right for Men?

The Wegovy pill launched in January 2026 at $149/month. Is a daily pill or weekly injection the better choice for men? We break down the data.

The Oral Wegovy Pill: What It Is

FDA-approved in December 2025 and launched in January 2026, the Wegovy pill is the first oral GLP-1 medication approved specifically for weight loss. It contains semaglutide — the same active ingredient as injectable Wegovy and Ozempic — in a once-daily tablet formulation.

Available doses include 1.5mg, 4mg, 9mg, and 25mg tablets, following a 12-week dose escalation to the target 25mg dose.

Head-to-Head Comparison

Factor	Wegovy Pill (25mg)	Wegovy Injection (2.4mg)
Dosing	Once daily	Once weekly
Weight loss (adherent)	16.6%	~15%
Weight loss (all patients)	13.6%	~12-13%
Self-pay price	$149/month	$349/month
Insurance co-pay	~$25/month	~$25/month
Refrigeration	Not required	Required (36-46°F)
Empty stomach rule	Yes — 30 min before eating	No restriction
Needle	None	Yes (auto-injector pen)
Cardiovascular benefit	Yes (based on SELECT trial)	Yes

Why Men Might Prefer the Pill

Survey data consistently shows that a significant percentage of men avoid GLP-1 treatment specifically because of needles. The oral option removes that barrier entirely. Other advantages for men:

• Travel-friendly: No cold chain storage means you can throw it in a bag without worrying about temperature
• Discretion: Taking a pill is less conspicuous than injecting in shared spaces like gym locker rooms or offices
• Cost: At $149/month self-pay, it's less than half the price of the injectable
• Equivalent results: The OASIS 4 trial showed 16.6% weight loss with full adherence — matching or slightly exceeding the injectable

Why the Injection Might Be Better

The injectable still has legitimate advantages:

• Once-weekly convenience: One injection per week vs. remembering a daily pill with food timing restrictions
• No empty stomach requirement: The pill must be taken on an empty stomach with a small amount of water, then you wait 30 minutes before eating or taking other medications
• Higher dose now available: Wegovy HD (7.2mg) just approved May 2026 delivers 20.7% weight loss — no oral equivalent exists at this potency
• Proven long-term data: The injectable has years of real-world outcomes data

The OASIS 4 Trial: Key Details

The pivotal trial for oral Wegovy enrolled 307 adults with obesity or overweight. Participants took either oral semaglutide 25mg or placebo once daily for 64 weeks alongside lifestyle intervention.

Results for patients who stayed on treatment:

• Average weight loss of 16.6% vs. 2.7% with placebo
• 76.3% achieved at least 5% weight loss vs. 31.3% with placebo
• 34.4% achieved at least 20% weight loss vs. 2.9% with placebo
• Improvements in blood pressure, cholesterol, triglycerides, and waist circumference
• Over 70% of participants with prediabetes normalized blood glucose

What About Compounded Options?

Compounded semaglutide injectables remain available through telehealth providers at $130-$300/month, though FDA regulatory pressure is increasing. These offer a lower price point than brand-name injectables while maintaining the once-weekly injection format.

Provider Options at Every Price Point

The Bottom Line

For men who've avoided GLP-1 treatment because of needles or cost, the Wegovy pill is a genuine breakthrough — same active ingredient, comparable weight loss, half the price, no refrigeration. For men who prefer once-weekly dosing and want maximum potency, the injectable (especially the new HD formulation) delivers more weight loss per dose. Either way, the options for men in 2026 are dramatically better than even 12 months ago.